

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sinohealth Holdings Limited

中康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 2361)

POSITIVE PROFIT ALERT

This announcement is made by Sinohealth Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) (a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The Company would like to inform the shareholders and potential investors of the Company that, based on the preliminary assessment of the Group’s latest unaudited consolidated management accounts for the year ended 31 December 2023 (the “**FY2023**”), the profit attributable to equity holders of the Company for FY2023 is expected to be not less than RMB100 million, representing an increase of approximately 85% as compared with that for the year ended 31 December 2022 (“**FY2022**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is of the view that the increase in profit was mainly due to (i) further increase in revenue from the Group’s principal business in FY2023 as compared to the same period last year due to the Group’s comprehensive solution which offers a combination of various digital insight products and professional services facilitating customers in cost reduction, efficiency enhancement and business expansion against the increased demands for digitalization in the healthcare industry; (ii) the comprehensive improvement of the Group’s efficiency in operational management and market expansion in FY2023; and (iii) in part, the increase in other income such as interest income.

As at the date of this announcement, the Company is currently in the process of finalizing the annual results of the Group for the year ended 31 December 2023. The information as set out in this announcement is the Board’s preliminary assessment with reference to the Group’s unaudited consolidated management accounts for FY2023 and the information currently available to the Board. Such information has neither been audited and confirmed by the Company’s independent auditors nor reviewed by the audit committee of the Company and is subject to adjustments. The Company’s annual results announcement for FY2023 will be published by the end of March 2024, in compliance with the Listing Rules. Shareholders and potential investors are advised to read carefully the annual results announcement of the Company for FY2023.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Sinohealth Holdings Limited
Wu Yushu
Chairman

Hong Kong, 29 February 2024

As of the date of this announcement, the executive Directors are Mr. Wu Yushu and Ms. Wang Lifang, the non-executive Director is Mr. Fu Haitao, and the independent non-executive Directors are Ms. Wang Danzhou, Ms. Du Yilin and Mr. Wei Bin.